Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study

What Was Tested

This randomized controlled trial paper looks at Exenatide in the context of low blood pressure and orthostatic hypotension.

This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP) and triglycerides after 28 weeks' treatment with exenatide once weekly plus dapagliflozin, as compared with exenatide once weekly or dapagliflozin, in patient subpopulations from the DURATION-8 trial of patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone.

Subgroups of patients were stratified according to their baseline body weight, SBP and triglyceride levels.

Who Took Part

According to the abstract, 8 patients were involved.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Exenatide.

A time span of 28 weeks appears in the methods.

What Was Measured

This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP) and triglycerides after 28 weeks' treatment with exenatide once weekly plus dapagliflozin, as compared with exenatide once weekly or dapagliflozin, in patient subpopulations from the DURATION-8 trial of patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone.

Subgroups of patients were stratified according to their baseline body weight, SBP and triglyceride levels.

Topics PubMed links to this paper include Anti-Obesity Agents, Benzhydryl Compounds, Blood Pressure, Body Mass Index, Diabetes Mellitus, Type 2, Exenatide and Glucosides.

The authors tagged it with the keywords GLP-1 analogue, SGLT2 inhibitor, dapagliflozin and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exenatide in 8 patients in people with low blood pressure and orthostatic hypotension over 28 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page, Low blood pressure and orthostatic hypotension research.